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Glioblastoma multiforme (GBM) is the most frequent and devastating primary brain tumor in adults. Despite current
treatment modalities, such as surgical resection followed by chemotherapy and radiotherapy, only modest
improvements in median survival have been achieved. Frequent recurrence and invasiveness of GBM are likely due
to the resistance of glioma stem cells to conventional treatments; therefore, novel alternative treatment strategies
are desperately needed. Recent advancements in molecular biology and gene technology have provided attractive
novel treatment possibilities for patients with GBM. Gene therapy is defined as a technology that aims to modify
the genetic complement of cells to obtain therapeutic benefit. To date, gene therapy for the treatment of GBM has
demonstrated anti-tumor efficacy in pre-clinical studies and promising safety profiles in clinical studies. However,
while this approach is obviously promising, concerns still exist regarding issues associated with transduction
efficiency, viral delivery, the pathologic response of the brain, and treatment efficacy. Tumor development and
progression involve alterations in a wide spectrum of genes, therefore a variety of gene therapy approaches for
GBM have been proposed. Improved viral vectors are being evaluated, and the potential use of gene therapy alone
or in synergy with other treatments against GBM are being studied. In this review, we will discuss the most
commonly studied gene therapy approaches for the treatment of GBM in preclinical and clinical studies including:
prodrug/suicide gene therapy; oncolytic gene therapy; cytokine mediated gene therapy; and tumor suppressor
gene therapy. In addition, we review the principles and mechanisms of current gene therapy strategies as well as
advantages and disadvantages of each.
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Introduction
Gliomas are the most frequently occurring primary brain
tumor in adults. Glioblastoma multiforme (GBM) is the
most aggressive form and least curable [1]. The current
standard of treatment consists of maximal surgical re-
section followed by radiation and temozolomide (TMZ)
chemotherapy [2]. Despite recent reports that demon-
strate a two-month survival advantage when adjuvant
TMZ chemotherapy is used, the median survival still re-
mains less than 15 months and death ensues in most cases
within 2 years of diagnosis [3,4]. The high mortality ob-
served with GBM is due to a consequence of many con-
tributing factors including the aggressive and invasive* Correspondence: james.rutka@sickkids.ca
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unless otherwise stated.phenotype making radical surgical removal extremely dif-
ficult. In addition, GBM is often resistant to radiation and/
or chemotherapy. Chemotherapy may fail because of an
inability to effectively deliver reagents across the blood
brain barrier (BBB). The central nervous system is also
largely regarded as an immunologically privileged site,
and protected from systemic immune responses. This
presents a disadvantage with respect to the efficacy of
systemic immune-boosting strategies.
It is now generally accepted that all cancers contain a
small population of cells with stem cell like properties
called cancer stem cells (CSCs). The concept of the CSC
has been extended to brain tumors, including GBM, and
it is now being exploited as a therapeutic target. Glioma
stem cell (GSCs) are capable of asymmetric cell division
into self-renewing GSCs and differentiating daughter
cells that can gain different phenotypes, subsequently
losing their multipotent property [5]. Disease progres-
sion and an inevitable recurrence after therapy are mosttd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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resistant to radiotherapy and chemotherapeutic agents
[6-8]. Unfortunately, despite the significant progress
achieved by surgery and adjuvant chemoradiotherapy in-
cluding molecular-targeted approaches in the treatment
of disseminated malignancies, the prognosis of GBM re-
mains unsatisfactory. Therefore, novel and more efficient
strategies are urgently needed, and real progress can only
emerge from increasing our understanding of the molecu-
lar biology of these tumours, and through the discovery of
novel mechanisms for the delivery of tumoricidal agents.
Gene therapy can be defined as the treatment of disease
by the introduction of a therapeutic gene or the manipula-
tion of a disease-related gene such as abrogation of an ac-
tivated oncogene within target cells [9]. Owing to a better
understanding of the mechanisms of virus interactions
with the cell and the advancement of recombinant deoxy-
ribonucleic acid (DNA) technology, it is now possible to
take advantage of the tumor cell-specific genetic defects
and to construct viral strains that replicate selectively in
tumor cells. To date, gene therapy has been applied to
several types of cancer [10]. One of the most dismal
types of cancer, GBM is an ideal target for gene therapy
given that current standard therapies remain minimally
effective and that GBM rarely metastasizes to other
locations in the body.
The first clinical trials of gene therapy targeting gliomas
were published in the 1990’s [11,12]. Different methods,
including: viral vectors; cellular carriers (neural stem cell,
mesenchymal stem cell, or embryonic stem cell); and
synthetic vectors using nanotechnology (nanoparticle or
cationic liposome) have been studied and employed as a
vehicle to deliver genes into the target cells. Although
stem cells as vehicles have only recently reached clinical
study, they promise to be one of the most attractive vec-
tors to combine gene therapy with other type of therap-
ies. The only synthetic vector that has reached clinical
trials against glioma to date is a cationic liposome which
was employed as a small molecule carrier [13,14]. Al-
though, gene transfer using liposomes is considered
safe, it has been used infrequently due to limited gene
transfer efficiency. On the other hand, viral vectors are
considered to be the most effective of all gene delivery
methods for in vivo gene transfer [15]. Currently, the
most frequently used DNA delivery vehicles are genet-
ically modified viruses or vectors. There are two types
of viral vectors used for anti-glioma therapy. The first
uses replication-deficient viruses capable of transdu-
cing genes into the tumor cells resulting in detrimental
intracellular effects; and the second employs oncolytic
viruses where the replicating viruses have a lytic cycle,
and selectively kills tumor cells. Among all viral vec-
tors, adenovirus (AV), retrovirus, herpes simplex virus
(HSV), and adeno-associated virus (AAV) are currentlythe most widely employed delivery vectors used in
gene therapy in patients with cancer [15,16].
There are a wide variety of strategies for gene therapy
of GBM. In addition to the large number of vectors and
their individual features, different transgenes provide dis-
tinct ways of eliciting an anti-tumoral response. Conse-
quently, gene therapy is a viable option for the treatment
of GBM. In this article, we will review (i) the major ap-
proaches used for gene therapy against GBM including
prodrug/suicide gene therapy, oncolytic gene therapy,
cytokine mediated gene therapy, and tumor suppressor
gene therapy; (ii) the rationale for the design of vectors;
(iii) mechanisms of the vectors replication in tumor cells;
(iv) discuss advantages and disadvantages of each gene
therapies and future direction.
Approaches to gene therapy
Suicide gene therapy
The most commonly used gene therapy strategy against
malignant glioma in preclinical study and in clinical trials
is suicide gene therapy [17]. Suicide gene therapy is a
strategy that involves introduction of a viral or a bacterial
gene into tumor cells resulting in the conversion of a non-
toxic compound into lethal active molecules capable of
inducing tumor cell death [18]. A critical factor in this
strategy is that the gene encodes an enzyme which con-
verts a prodrug into a cytotoxic drug. More importantly,
this strategy is based on evidence that prodrug-activating
enzymes are normally absent or expressed at low levels in
mammalian cells [19]. Consequently the tumor-targeting
viral vector is necessary to restrict enzyme expression to
the transduced tumor cells. Several suicide gene therapies
have been evaluated using adenoviral, retroviral, or
non-viral vector delivery methods in numerous clinical
trials [17,20-24]. The most widely investigated suicide
gene therapies against GBM are Herpes Simplex Virus
Thymidine Kinase (HSV-TK) gene therapy and Cytosine
Deaminase 5-fluorocytosine (CD/5-FC) [13,17,25-27].
The possibility of using HSV-TK as gene therapy was
first reported by Moolten in 1986 [28]. HSV-TK can
catalyze the phosphorylation of nucleoside analogues
such as ganciclovir (GCV: a synthetic analogue of 2′-
deoxy-guanosine) which is a poor substrate for the
mammalian TK. Following the systemic administration
of the inactive prodrug, GCV is converted by HSV-TK
into a toxic metabolite called GCV-triphosphate which
is incorporated into the DNA of actively proliferating
cells (Figure 1). GCV-triphosphate consequently blocks
DNA replication and inhibits cell division [28,29]. Apop-
tosis underlies the mechanism of cytotoxicity induced by
the HSV-TK/GCV gene therapy [30]. The HSV-TK gene
therapy is cell cycle dependent. Therefore, one of the
advantages of this therapy is that it exhibits selective
cytotoxicity to only actively dividing cells transduced
Figure 1 Strategy for suicide gene therapy. The aim of suicide gene therapy strategy is to increase the delivery of toxic metabolites to tumor
cells and result in efficient cell death. Initially, a gene encoding a prodrug-activating enzyme is delivered by a tumor-targetting viral vector.
Subsequent systemic administration of an inactive prodrug results in generation of a toxic metabolite and cell death of the transduced cells and
non-trasduced bystander tumor cells (bystander effect) only at the tumor site.
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stander effect where toxicity is transferred directly from
infected cells to adjacent non-infected cells thereby enhan-
cing the treatment effect [31]. A possible mechanism that
can account for this effect is that non-transduced cells are
killed by the spread of phosphorylated nucleoside ana-
logues through gap-junctions, facilitated by cell-to-cell
contacts [15,32-34]. A second possible mechanism is the
accumulation of phosphorylated nucleoside analogues in
neighboring cells inducing apoptosis of non-transduced
cells [35,36]. A third mechanism may involve phagocytosis
induced by neighboring transduced cells as a result of
apoptotic vesicle formation. Several cellular compo-
nents could be shared with the neighboring cell during
this process resulting in the delivery of an apoptotic
signal [37].
HSV-TK/GCV gene therapy has demonstrated prom-
ising results in animal models [12,38]. Recently, these
results have prompted clinicians to examine HSV-TK/
GCV gene therapy for glioblastoma. Multiple Phase I
and II clinical trials demonstrated that HSV-TK/GCV
gene therapy is a relatively safe strategy [21,39]. There is
some evidence, however, suggesting that HSV-TK trans-
duced cells may become resistant to the prodrug, there-
fore requiring combination of suicide gene therapy with
chemo-radiotherapy [25,40-42]. One of the largest ran-
domized Phase III clinical trials was conducted by Rainov,
where 248 patients with newly diagnosed, previously
untreated GBM, were randomized into a control group
(surgical resection and radiotherapy) or gene therapy
group (surgical resection and radiotherapy plus adju-
vant replication-competent retrovirus mediated HSV-
TK/GCV gene therapy during surgery). Although this
trial proves that HSV-TK gene therapy was safe, there
was no difference in median survival and tumor pro-
gression between groups. Unfortunately, based on thesedata, there was no therapeutic benefit of retrovirus me-
diated HSV-TK gene therapy. The authors concluded
that improved high efficiency delivery and distribution
strategy of therapeutic genes is likely necessary [43].
Despite promising results in vitro and in vivo, the anti-
tumor effect of retrovirus mediated HSV-TK gene ther-
apy in clinical trials remains insufficient due to very low
transfection efficiency. In support of this, Sandmair
et al. reported a Phase I clinical trial of 21 patients diag-
nosed with primary or recurrent GBM who were treated
with replication-defective retrovirus or adenovirus. The
results of this study showed that the median survival of
the adenovirus mediated HSV-TK/GCV gene therapy
group was significantly longer than the retrovirus medi-
ated group [22]. Germano et al. also reported the safety
of replication-defective adenoviral-mediated HSV-TK
gene therapy in a Phase I trial, where the average sur-
vival of the treatment group was 112.3 weeks and one
patient survived as long as 248 weeks from diagnosis.
Collectively these trials indicate that using adenovirus
to deliver the HSV-TK gene may be better in contrast to
retroviral vectors [21]. At least 10% transfection effi-
ciency is needed in order to obtain a significant reduc-
tion in tumor volume based on the results of the rat
glioma xenograft experiments [44]. Clinical trials utiliz-
ing adenoviral delivery suicide gene therapy for glioma
are currently underway (Table 1).
Suicide gene therapy using cytosine deaminase/5-
fluorocytosine (CD/5-FC) has been an extensively studied
form of anti-glioma gene therapy [17]. CD is a microbial
or a yeast enzyme capable of converting an effective anti-
fungal drug, 5-FC, to the highly toxic anti-cancer com-
pound 5-fluorouracil (5-FU) [45,46]. Since CD is absent in
mammalian cells, 5-FC has minimal human toxicity.
The toxic effects of 5-FU are mediated by the conver-
sion of 5-FU to 5-FU triphosphate which interferes with
Table 1 Ongoing clinical trials for gene therapy of GBM
Type of
gene therapy Phase Vector Gene Prodrug Nation ID Title
Suicide Pilot NSC CD 5-FC USA NCT01172964
A Pilot Feasibility Study of Oral 5-Fluorocytosine
and Genetically-Modified Neural Stem Cells
Expressing E. Coli Cytosine Deaminase for
Treatment of Recurrent High Grade Gliomas
Suicide I AV HSV-TK Valacyclovir USA NCT00751270
Phase 1b Study of AdV-tk + Valacyclovir Combined






Combined Cytotoxic and Immune-Stimulatory




CD 5-FC USA NCT01470794
Study of a Retroviral Replicating Vector to Treat





CD 5-FC USA NCT01985256
Study of a Retroviral Replicating Vector Given
Intravenously to Patients Undergoing Surgery for
Recurrent Brain Tumor
Suicide I AV HSV-TK Valacyclovir USA NCT00634231
A Phase I Study of AdV-tk + Prodrug Therapy in





CD 5-FC USA NCT01156584
A Study of a Retroviral Replicating Vector
Administered to Subjects With Recurrent Malignant
Glioma
Suicide II AV HSV-TK Valacyclovir USA NCT00589875
Phase 2a Study of AdV-tk With Standard Radiation




- - USA NCT02031965
Oncolytic HSV-1716 in Treating Younger Patients
With Refractory or Recurrent High Grade Glioma
That Can Be Removed By Surgery















- - USA NCT00805376 DNX-2401 (Formerly Known as Delta-24-RGD-4C)




LacZ - Japan JPRN-
UMIN000002661
A Clinical Study of a Replication-Competent,
Recombinant Herpes Simplex Virus Type 1 (G47delta)




- - Germany NCT01301430 Parvovirus H-1 (ParvOryx) in Patients With Progressive




- - Netherlands NCT01582516 Safety Study of Replication-competent Adenovirus




- - Netherlands EUCTR2007-
001104-21-NL
A Phase I/II Trial of a Conditionally Replication-
Competent Adenovirus (delta-24-rgd) Administered
Convection Enhaced Delivery in Patients With
Recurrent Glioblastoma Multiforme
*Suicide I NSC CD 5-FC USA NCT02015819
Genetically Modified Neural Stem Cells, Flucytosine,
and Leucovorin Calcium in Treating Patients With
Recurrent High-Grade Gliomas
*Oncolytic I/II NDV - - Israel NCT01174537 New Castle Disease Virus (NDV) in Glioblastoma
Multiforme (GBM), Sarcoma and Neuroblastoma
*Oncolytic/
immune-mediated
I HSV (M032) IL-2 - USA NCT02062827 Genetically Engineered HSV-1 Phase 1 Study
A search was conducted on a publically available online database made available by the U.S. National Institutes of Health (http://clinicaltrials.gov/) and
International Clinical Trials Registry Platform (http://apps.who.int/trialsearch/Default.aspx) as of February 2014. Abbreviations: 5-FC, 5-fluorocytosine; AV, adenovirus;
CEA, carcinogenic embryonic antigen; CD, cytosine deaminase; Flt3L, fms-like tyrosine kinase-3 ligand; HSV, herpes simplex virus; IL, interleukin; MV, measles virus;
NDV, new castle disease virus; NSC, neural stem cell; PaV, parvovirus; PoV, poliovirus; RV, retrovirus; TK, thymidine kinase; *, registered but not yet recruiting.
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5-fluoro-2′-deoxyuridine 5′-monophosphate, which ir-
reversibly inhibits thymidylate synthase, and blocks
DNA synthesis (Figure 1) [19]. Similar to HSV-TK gene
therapy, apoptosis underlies the cytotoxic mechanism
of CD/5-FC gene therapy [30,47]. 5-FU is a small mol-
ecule that can diffuse in and out of transduced and
neighboring cells, resulting in significant bystander ef-
fects which do not require cell-cell contact and func-
tional gap junctions [48,49]. In comparison to HSV-TK
gene therapy, CD/5-FC gene therapy demonstrated a
greater anti-tumor effect when observed in a colorectal
xenograft tumor model where only 4% of tumor cells are
transduced [50]. Dong et al. reported that replication-
deficient adenovirus vectors carrying the CD gene and
subsequent administration of 5-FC resulted in significant
prolonged survival in glioma-bearing rats [51]. Several
attempts have been made to increase the efficacy of CD/
5-FC gene therapy. Adachi et al. reported that a second
enzyme, uracil phosphoribosyltransferase (UPRT), which
is absent from mammalian cells, directly converts 5-FU
into 5-fluorouridine monophosphate which enhances the
cytotoxicity of CD/5-FC gene therapy in an experimental
malignant brain tumor, suggesting that co-expression of
CD and UPRT genes have synergistic anti-tumor effects
[52]. In addition, the combination of CD/5-FC and UPRT
gene therapy also enhances conventional radiotherapy in
an animal model of glioma [53]. Further enhancement of
cytotoxicity is accomplished by using replication-defective
adenoviral vector encoding a mutant bacterial CD gene
with increased affinity for 5-FC [19]. The combination of
this recombinant CD gene with ionizing radiotherapy has
shown significant tumor cell killing and inhibition of
tumor growth in glioma xenograft models [19]. Recently, a
second generation non-lytic retroviral replicating vector
(Toca 511) demonstrated stable delivery of CD resulting
in significant survival benefit without treatment related
toxicity in a mouse glioma model [54]. Furthermore, syn-
ergistic therapeutic efficacy of TMZ, which is the most fre-
quently used treatment for patients with GBM, was
observed in combination with Toca 511 with subsequent
administration of 5-FC resulting in a survival advantage in
mice bearing TMZ-sensitive glioma [55].
A novel approach to suicide gene therapy involves the
use of genetically engineered neural stem cells as a vec-
tor. Neural stem cells have the ability of continuous
proliferation and differentiation into neuronal or glial
cells [56-58]. One of the great advantages of using
neural stem cells as a vector for GBM therapy is their
invasive capability directed towards tumor cells, even
when injected adjacent to the tumor [59,60]. Genetically
engineered neural stem cells have been successfully
used to deliver CD and HSV/TK gene products into
GBM [59,61,62].CD/5-FC gene therapy has reached clinical trials and
Toca 511 or genetically modified neural stem cells used
as vectors are currently under investigation in patients
with recurrent high grade glioma [54,55] (Table 1). An
additional type of stem cell vector is the mesenchymal
stem cell. Mesenchymal stem cells are non-hematopoietic,
multipotent stem cells. In comparison to neural stem cells,
mesenchymal stem cells have advantages because they are
easily acquired from patient tissues such as bone marrow,
adipose tissue, muscle tissue, and peripheral blood stream
[27,63]. Their intrinsic ability to migrate to the site of in-
jury and inflammation allows them to invade into tumors
[64]. Owing to this strong homing behavior, mesenchymal
cells have been used as a vector for gene therapy against
glioma [65]. Some suicide gene therapies have employed
mesenchymal stem cells as a vector, including HSV/TK,
CD, and HSV/TK combined with connexin-43 to enhance
bystander effect [66-68].
Oncolytic gene therapy
A substantial focus in viral vector development has been
the creation of genetically engineered adenoviruses and
retroviruses. However, researchers are confronted with
the limitations of their low efficiency for distribution, de-
livery to target cells and difficulties in achieving prolonged
efficacy. Oncolytic gene therapy employs replication-
competent viral vectors in order to increase the toxicity
and efficiency against the tumor. Oncolytic viral vectors
have the ability to selectively replicate in target tumor
cells, and then to release viral particles and to spread
to new adjacent progeny cells as the host cell is lysed
(Figure 2A). Although, in some studies, immunosuppres-
sion has been shown to improve viral oncolytic effect,
there is increasing evidence that oncolytic gene therapy
will ultimately require an antitumor immune response as
well as disruption of the tumor microenvironment such as
inhibition of angiogenesis [10,69-74]. The transduction
efficiency of replication-competent viral vectors in tu-
mors is significantly higher than that of replication-
deficient viral vectors [17]. Oncolytic HSV, conditionally
replicating adenovirus, measles virus (MV), poliovirus
(PoV), Newcastle disease virus, parvovirus (H1-PV), and
reovirus have all been employed and clinically tested in
oncolytic gene therapy strategies for GBM (Table 1)
[17,27,75]. Below, we describe the strategies for anti-
glioma oncolytic viral therapy.
HSV-1 is an enveloped double strand DNA virus with
neurotropic properties capable of replication in dividing
and non-dividing cells [13,76,77]. Wild type HSV-1 may
either proceed to a lytic life cycle or stay in an intranuclear
episome which is never integrated into the host genome.
An advantage of an HSV-1 mediated approach is the doc-
umented sensitivity to acyclovir and GCV, thus adding to
its safety profile. G207 is a conditionally replicating HSV
Figure 2 Strategy and mechanism for oncolytic gene therapy. (A); Oncolytic gene therapy employs replication-competent virus vectors
capable of selective replication in target tumor cells. Spreading to new adjacent progeny cells occurs as the host cell is lysed and progeny virus
is released. (B); Most viruses can replicate poorly in normal cells by a defense mechanism as follows. In response to viral infection, Protein Kinase
R (PKR) in the host cells shut off protein synthesis by which PKR dimerizes and is inactivated by autophosphorylation resulting in the conversion
of eukaryotic initiation factor-2 alpha (EIF-2α) into its inactive state following phosphorylation, which is required for translation initiation. Consequently,
translation is arrested in the infected host cells as an anti-viral protective mechanism. However, the ICP34.5 in HSV-1 can overcome this defense
by recruiting protein phosphatase-1α to dephosphorylate EIF-2α allowing protein synthesis to proceed. Therefore, when a deletion of γ34.5 gene is
engineered, the HSV-1 mutant can no longer successfully proliferate in non-replicating cells. HSV-1 lacking ICP34.5 activity can only infect cells with
defective PKR pathway. In tumor cells, PKR autophosphorylation is blocked due to Ras activation, permitting replication of viruses lacking the γ34.5
gene in tumor cells with hyper-activated Ras.
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strain lacking the genes necessary for viral replication in
normal cells. G207 has a deletion in both copies of γ34.5
gene which encodes for the protein synthesis promoting
factor infected cell protein (ICP) 34.5. In addition, the
Unique Long (UL) 39 gene is inactivated by an insertion of
the LacZ reporter gene into the region of the UL39 gene
encoding ICP6, thereby disrupting the large subunit of the
enzyme ribonucleotide reductase (RR) [78]. The enzyme,
RR, is crucial for nucleotide synthesis after infection of
post-mitotic cells such as neurons [79,80]. Oncolytic HSV
virus which has an impaired RR cannot replicate in non-
dividing cells but can replicate only in dividing cells, which
is due to the mitotic cells providing cellular RR andcircumventing the need for viral RR. Therefore, oncolytic
viruses which have mutation in UL39 gene can achieve ef-
fective lytic activity only in dividing cells such as malig-
nant glioma. However, it was estimated that only 5-15% of
malignant glioma cells are in mitotic phase at any moment
in time, meaning that the majority of malignant glioma
cells can escape this type of oncolytic gene therapy
[81,82]. However, the ICP6-defective HSV retains signifi-
cant replicative ability in p16-deficient cells independent
of cell cycle status [81]. Therefore, G207 can target non-
dividing cells with p16 deletion or inactivation [81].
An added safety advantage of the RR-deficient virus,
G207, is modest hypersensitivity to anti-viral agents such
as acyclovir and GCV [83]. The bacterial reporter gene
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tribution of viral infection within the target tissues [84].
The neurovirulence gene, γ34.5 is crucial to overcome
host cell defense mechanisms after infection. During
viral infection, a stress response is initiated by the host
cells. Protein Kinase R (PKR) activation arrests translation
in the infected host cells in order to induce an anti-viral
protective mechanism by phosphorylating and inactivating
eukaryotic initiation factor-2 alpha (EIF-2α) which is re-
quired for the initiation of translation. However, ICP34.5
in HSV-1 recruits protein phosphatase-1α to dephosphor-
ylate EIF-2α and promote protein synthesis (Figure 2B)
[85]. HSV-1 lacking ICP34.5 activity can only infect cells
with a defective PKR pathway [86]. In tumor cells, PKR
autophosphorylation is blocked due to Ras activation;
therefore it allows selective replication of the viruses lack-
ing the γ34.5 gene in tumor cells with hyper-activated Ras
(Figure 2B) [84,87-89]. UL39 gene encoding RR is crucial
for virus replication given its functional role in catalyzing
the formation of ribonucleotides, which are essential to
nucleotide synthesis from ribonucleotides. Therefore RR is
critical for viral DNA synthesis. Virus replication depends
on RR in normal non-dividing cells; therefore the lack of
viral RR expression in the G207 is compensated for by the
tumor cells with high RR activity which results in highly
specific targeting of tumor cells.
Preclinical studies using G207 demonstrated decreased
tumor growth in experimental gliomas and a high safety
profile [78,90-93]. Based on these results, G207 mediated
oncolytic therapy was taken to clinical trials to begin
evaluating its efficacy in anti-glioma therapy. Markert
et al. reported a Phase I clinical trial using G207 in 2000
[94]. In total, 21 patients with progressive malignant gli-
oma were enrolled. The trial demonstrated no treatment-
related toxicity or serious adverse events; and no evidence
of HSV encephalitis was observed. A positive therapeutic
response was identified in eight patients, and one patient
survived 5.5 years after the treatment. A maximally toler-
ated dose could not be determined because there were no
dose-limiting toxicity even with inoculation of 3 × 109
Plaque-Forming Units (PFUs) [94]. In a Phase Ib study, six
patients with recurrent glioma received G207 inoculation
totaling 1.15 × 109 PFUs both prior to surgery and post
operatively. The virus was injected either directly into the
tumor or into the resected tumor cavity using a stereotac-
tically guided catheter. Three of the patients showed sub-
sequent improvement and the overall survival was greater
than six months. In this study, there was no evidence of
virus-related toxicities and G207 gene therapy was
shown to have an excellent safety profile for repeated
dose delivery as well as direct injection into the resected
tumor cavity [95].
Another genetically engineered HSV-1 mutant is
HSV1716, derived from the parent wild-type strainHSV-1 17+ [96]. This conditionally replicative mutant
virus has a 759 bp deletion in both copies of γ34.5
gene, inactivating the ICP34.5 protein and the intact
UL39 gene. HSV1716 is capable of replication in divid-
ing cells but not differentiated cells, conveying tumor
cell selectivity similar to G207. In 1994, Valyi-Nagy
et al. demonstrated that HSV1716 was nonvirulent in
severe combined immunodeficiency mice making it a
promising candidate for oncolytic gene therapy [97].
Moreover, the studies in animal models supported pur-
suing HSV1716 as a potential novel treatment strategy
for malignant brain tumors [98-100]. The promising
safety and efficacy profiles allowed HSV1716 to be tested
for anti-glioma therapy in humans. As with G207, the
safety and toxicity of HSV1716 administration in patients
was first demonstrated in a Phase I clinical trial consisting
of nine patients with recurrent glioma that received
stereotactic intratumoral injections. Prior to the start of
therapy, all patients had undergone surgery and radiother-
apy and six patients received chemotherapy. Four patients
remained alive for 14–24 months after the virus admin-
istration. None of the patients demonstrated signs of
encephalitis following treatment, and there was no need
to use anti-herpetic medication. It was remarkable that
no major neurological manifestation was noted. The
treatment decelerated tumor growth and increased the
survival to three years in one patient and to four years
in two patients. In this trial, a dose escalation study was
also carried out with the initial doses of 1× 103 to 1 ×
105 PFUs. A maximum tolerated dose was not deter-
mined because the highest dose used in this study
showed no adverse effects [101].
In a subsequent Phase Ib trial, Papanastassiou et al.
demonstrated replication activity of HSV1716 within the
tumors. All patients enrolled in this trial were inoculated
with 1 × 105 PFUs intratumorally, and then underwent
tumor resection four to nine days after injection. The
resected tumors were analyzed for viral replication activ-
ity. While no treatment related toxicity was observed,
there was evidence of viral replication upon histological
examination [102]. A third clinical study was reported
by Harrow in 2004 [103]. In this study, 12 patients with
recurrent or newly diagnosed GBM underwent surgical
resection. HSV1716 was injected into multiple sites around
the resection cavity and none of the patients showed viral
injection-related toxicity. Three patients demonstrated
clinically stable disease and increased survival following
surgery and viral injection at 15, 18, and 22 months
[103]. HSV1716 has also been clinically used for ad-
vanced melanoma [10,104]. In three patients receiving
multiple intranodular injections, immunohistochemical
staining of injected nodules revealed evidence of virus
replication confined to tumour cells without toxic ef-
fects [105]. Taken together, these studies show that
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glioma therapy as well as other types of cancer. How-
ever, one drawback of these models is the required dele-
tion of γ34.5 genes which reduces the viral replication
ability, and limits its efficacy [106].
Oncolytic HSVs which have deletions in both copies of
γ34.5 genes have limited or no replication in GSCs [107].
G47Delta is the new generation of oncolytic HSV. In order
to restore GSC sensitivity, G47Delta has an additional de-
letion of the gene encoding ICP47 resulting in enhanced
major histocompatibility complex (MHC) class I antigen
presentation and enhanced immune response [107,108].
In addition, this deletion causes promoter shift for the
unique short 11 gene which blocks the effect of inter-
ferons and consequently to increase virus replication in
tumor cells [108,109]. G47Delta is being examined in
pre-clinical models and preparing to proceed to clinical
trials [108,110-112]. A Phase I/II clinical trial using
G47Delta which further enhances specificity and safety
is currently underway evaluating the efficacy and safety
for recurrent or progressive GBM (Table 1).
AV are nonenveloped viruses with double strand DNA
capable of infecting both proliferating and quiescent cells.
AV vectors enter central nervous system (CNS) cells by
receptor-mediated endocytosis; however, they are not inte-
grated into cellular DNA, but exist as episomes in which
AV’s DNA is transcribed and translated using the intrinsic
cellular machinery [113]. Given that AV’s are not inserted
into the host genome, there is minimal risk of insertional
mutagenesis. Two commonly investigated conditionally
replicating AVs in glioma are ONYX-015 (also known as
dl1520) and Ad5Delta24, both of which target cells with
impaired signaling pathways [17,27].
ONYX-015 has a deletion in the 55kD protein early
region 1B-55kD (E1B-55kD) which conveys a selective
phenotype to it [114]. E1B-55kD normally binds and inac-
tivates the tumor suppressor p53 preventing the induction
of p53 apoptosis in the infected cell before the virus cycle
is complete. Consequently, the cells with functional p53
protein cannot assist viral replication without E1B-55kD.
The absence of E1B-55kD results in selective replication
in p53-deficient tumor cells [114-116]. An important con-
sideration is that some studies have identified that there
are additional beneficial mechanisms that may provide
oncolytic activity of ONYX-015 in gliomas which are
p53-independent, and may even be increased in p53 in-
tact glioma cells [117-120]. Preclinical studies of ONYX-
015 in human malignant glioma xenografts derived from
primary tumors demonstrated a high anti-tumor activity
and widespread intratumoral replication in p53 wild-type
tumors as well as p53-mutant tumors [117]. Furthermore,
the efficacy of oncolytic therapy of the virus was enhanced
by radiation therapy [121]. ONYX-015 is a promising
agent for further anti-glioma research in animal modelstudies, and ONYX-015 needs to be tested in clinical
trials for malignant glioma [117]. The initial Phase I
dose-escalation clinical study in brain tumors was con-
ducted in 24 patients with recurrent malignant glioma
who were subdivided into four groups of six patients.
Each patient received ONYX-015 at a dose from 1 × 107
PFUs to 1 × 1010 PFUs injected into 10 different sites
within the tumor bed cavity following surgical resection.
None of the patients showed serious adverse effects re-
lated to ONYX-015; however, the maximum tolerated
dose was not reached, even at the highest dose of 1 ×
1010 PFUs. The median time to progression and the me-
dian survival time were 46 days and 6.2 months, respect-
ively. Despite ONYX-015′s promising safety profile, there
was no observable significant therapeutic benefit [122].
ONYX-015 was also used in clinical trials for other types
of cancer such as squamous cell carcinoma and hepatobili-
ary carcinoma [10]. In contrast to the clinical trial for gli-
oma, they showed anticancer effect without significant
adverse effects [10,123-125]. These results suggest that
ONYX-015 could be applied more effectively to patients
with an earlier stage of GBM.
The Ad5Delta24 has a 24 bp deletion in the viral pro-
tein early region 1A. This deletion inhibits virus func-
tion by interfering with the retinoblastoma (Rb) protein.
Normally, phosphorylated Rb inhibits cell proliferation
by binding and inactivating the transcription factor E2F.
Infected cells with wild-type AV are transformed by
inhibiting Rb-hypoP (hypo-phosphorylated form of Rb)
in the proliferative phase of the cell cycle (G1 to S cell
phase). Rb is a tumor suppressor protein that functions in
a pathway that is commonly altered in gliomas [126,127].
In this manner, Ad5Delta24 can selectively replicate in gli-
oma cells with an impaired Rb pathway [128]. Preclinical
studies using the Ad5Delta24 demonstrated significant
growth inhibition of glioma xenografts in nude mice.
However, normal fibroblasts or cancer cells with intact Rb
activity were refractory to the viral therapy [128]. The
Ad5Delta24 was further genetically modified by the inser-
tion of the integrin-binding Arg-Gly-Asp (RGD) motif
into the fiber knob domain of the viral fiber protein, enab-
ling anchoring to integrins to enhance viral tropisms
(Ad5Delta24-RGD) [129]. Preclinical studies using this
vector with malignant glioma cell lines successfully dem-
onstrated that Ad5Delta24-RGD enhanced the specific
targeting of the tumor cells and increased the oncolytic ef-
ficacy against glioma. Furthermore, the survival of mice
harboring glioma xenografts that received an intratumoral
injection of Ad5Delta24-RGD was improved in compari-
son to the mice that received Ad5Delta24 control vector
[130]. An additional preclinical study in glioma xenografts
demonstrated that the oncolytic activity of Ad5Delta24-
RGD was enhanced by irradiation [131]. A Phase I and
I/II clinical trial using Ad5Delta24-RGD (DNX-2401) is
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malignant glioma (Table 1) [17,27,132].
MV, well-known as a human pathogen, is a single-
stranded, enveloped RNA virus belonging to the family
Paramyxoviridae. MV is known to be neurotropic and
rarely causes encephalitis. MV’s entry into cells requires
attachment of the hemagglutinin envelope glycoprotein
H to its cellular receptors such as CD46 and Signaling
Lymphocyte Activating Molecule followed by fusion with
the cell membrane through the envelope fusion glycopro-
tein F. These two glycoproteins play an important role for
oncolytic specificity and efficacy. Mutations in the H pro-
tein of the attenuated MV, known as the Edmonston strain
(MV-Edm), has a high affinity for cellular CD46 receptors
which are ubiquitously overexpressed in a wide range of
tumors [133-136]. The F protein is responsible for mem-
brane fusion and induces the formation of multinucleated
syncytia followed by apoptosis [137]. The MV-Edm was
genetically engineered to express the circulating carcino-
genic embryonic antigen (CEA) in order to monitor the
viral activity and maintenance of MV [138,139]. This MV-
CEA demonstrated favorable anti-tumor activity and
safety profile in animal models including a primary tumor
GBM xenograft model [75]. Based on these results, a
Phase I clinical trial of the MV-CEA strain in patients with
GBM is currently underway (Table 1) [17,27]. MV variants
have been engineered to express either interleukin (IL)-13
as a ligand to the GBM specific receptor IL-13Rα2 or a
single-chain antibody against the vIII deletion variant of
EGFR [140-142]. These MV variants have the capability
of targeting specific proteins expressed on glioma cells
thereby increasing their oncolytic activity and specificity.
PoV is a positive-sense, non-enveloped RNA virus with
natural neurotropism belonging to the Picornaviridae
family and is the virus responsible for human poliomyelitis
[136]. Viral neurotropism is attributed to the viral entry
receptor CD155 (also known as the poliovirus receptor)
which has been ectopically expressed and evaluated in
malignant glioma cells [143-145]. Viral neuropathogeni-
city is attributed to an internal ribosomal entry site (IRES),
located in the 5′ untranslated region of the poliovirus gen-
ome, which mediates viral protein translation [146]. In
order to eliminate the neurotoxicity, Gromeier et al. cre-
ated a recombinant intergeneric virus by replacing the
PoV IRES sequence with a nonpathogenic version from
human rhinovirus type 2 [147]. This recombinant PoV,
PVS-RIPO, is derived from the Sabin polio vaccine, which
has greatly diminished viral proliferation in normal neuron
cells while retaining significant lytic growth in malignant
glioma cells [143]. When delivered directly into the spinal
cord, PVS-RIPO significantly diminished poliomyelitis-like
neurotoxicity in both mice transgenic for the CD155 re-
ceptor and nonhuman primates [143,144]. Preclinical
studies of PVS-RIPO demonstrated significant biologiceffects. Treatment of athymic mice bearing intracerebral
glioma xenografts with PVS-RIPO attenuated tumor
progression and lead to tumor elimination [143]. Based
on these results, a Phase I clinical trial using PV-RIPO
is currently underway for application in recurrent ma-
lignant glioma (Table 1).
Stem cells used as carriers of oncolytic viruses have
become a promising approach because of their natural
tropism and ability to infiltrate solid tumors so that they
can deliver the viruses at further distance within large le-
sions [148]. There have been several examples demon-
strating the usefulness of using stem cells (neural stem
cells or mesenchymal stem cells) to deliver conditionally
replicating HSV and AV in preclinical studies [149-152].
As expected, the reach of viral delivery was strongly en-
hanced by using neural stem cells. Mesenchymal stem
cells carrying conditionally replicating AV has demon-
strated that the stem cell vector can suppress the immune
response against the virus, which makes it possible to pro-
long viral activity [152]. Intra-arterial delivery of mesen-
chymal stem cells carrying Ad5Delta24-RGD selectively
localized to human gliomas and were capable of delivering
and releasing Ad5Delta24-RGD into the tumor, resulting
in improved survival and tumor eradication in glioma
xenograft mouse models [153]. These results suggest
that stem cells carrying oncolytic virus may be adminis-
tered systemically and demonstrate viral delivery more
efficiently.
Cytokine mediated gene therapy
The underlying principle of cytokine mediated gene ther-
apy involves tumor-selective gene transfer and in situ ex-
pression of various cytokine genes such as IL-2, −4, −12,
and interferon (IFN)-β, −γ which can induce robust im-
mune responses restricted to antigens specific to glioma
cells [17,37,77,154]. Given that the CNS is relatively iso-
lated from the systemic immune system, gliomas can ef-
fectively evade the host immune response [13,27]. Several
physiological mechanisms unique to the CNS immune
system include lack of antigen-presenting cells such as
dendritic cells (DCs); lack of production of anti-
inflammatory mediators such as transforming growth
factor (TGF)-β; weaker expression of major MHC class
I and II; and the existence of BBB. These mechanisms
play important roles to protect the CNS from immuno-
logical attack (Figure 3). Therefore, it is challenging to
stimulate the immune system to develop an effective
anti-tumor response against gliomas [69]. Indeed, vari-
ous cytokines such as IFNs and IL have been used clin-
ically for the treatment of cancer, including chronic
myeloid leukemia, T cell and B cell lymphomas, melan-
oma, and renal carcinoma [155,156]. Several preclinical
studies have demonstrated the feasibility of mobilizing the
immune response against glioma cells. The susceptibility
Figure 3 Strategy of cytokine mediated gene therapy. Cytokine mediated gene therapy involves tumor-selective gene transfer and in situ
expression of various cytokine genes such as interleukin (IL) and interferon (IFN) capable of attracting immunocompetent cells such as macrophages
(MΦ), natural killer cells (NK), and cytotoxic T lymphocytes (CTL) inducing immune response.
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system provide the basis for developing anti-glioma
immune gene therapy based on immunomodulation.
Melanoma cells infected with a viral vector carrying the
gene for granulocyte-macrophage colony stimulating fac-
tor were injected subcutaneously in mouse. This cytokine
generated a strong immune response against intracranial
melanoma in the mouse model [157,158]. With regard to
the treatment for glioma, using various types of vectors
for cytokine gene delivery may allow local augmentation
of immune response. Since then, a variety of cytokines
such as interleukin and interferon gene therapies have
been studied to activate and enhance the effectiveness of
immune therapy against tumors.
IFN-β, type I interferon genes, are primarily produced
by specialize antigen presenting cells such as DCs post
viral infection [155]. IFN-β is an immunostimulatory
molecule inducing MHC class I expression, leading to
an increase in cytotoxic T cells activity, enhancing the
generation of T helper cells and activating natural killer
(NK) cells, DCs, and inducing macrophage activity
[154,155,159,160]. These immunomodulatory activities
can lead to a robust anti-tumor immune response. Qin
et al. reported a successful effect following IFN-β gene
delivery using a replication-deficient adenovirus under
the control of a cytomegalovirus (CMV) promoter [160].
Direct injection of the IFN-β gene with a replication-
deficient adenovirus demonstrated tumor regression in
human xenografts including glioma, through the activa-
tion of NK cells. Survival was significantly prolonged in
these mice [161]. Based on these results, an IFN-β-
expressing replication-defective AV was used in Phase I
clinical trials for recurrent malignant glioma. The 11 en-
rolled patients received stereotactic injection of the vector
into the tumor and surrounding intact brain following
resection. One out of 11 patients experienced treatment
related dose-limiting toxicity. Tumor histopathologicalanalysis revealed dose-related induction of apoptosis and
necrosis [162].
The use of a different type of vector, cationic lipo-
somes, was also used for IFN-β gene transfer. Local ad-
ministration of cationic liposomes containing the IFN-β
gene induced marked inhibition of tumor growth, NK
cell activation, and prolonged survival of mice bearing
human glioma xenografts [163,164]. In addition, cat-
ionic liposomes containing the IFN-β gene induced
cytotoxic T-cell immunity against mouse glioma cells
and marked tumor growth inhibition by activation of
the immune response in experimental gliomas [165,166].
Based on these results, this strategy reached a Phase I
clinical trial for recurrent malignant glioma. There was
no observable toxicity attributable directly to the use of
liposome. Two patients with anaplastic astrocytoma ex-
perienced more than 50% tumor reduction for at least
16 months [167]. Subsequent histological examination
demonstrated a dramatic change in the tumor tissue in-
cluding the presence of CD8 positive lymphocytes and
marked macrophage infiltration as well as apoptosis and
neovascularization [168]. The addition of IFN-β to
TMZ chemotherapy for patients with newly diagnosed
GBM results in a more favorable outcome than standard
therapy of TMZ alone [155,169]. Neural stem cells have
also been used to deliver a combination of CD and IFN-β
together to enhance the bystander effect and the immune
response against the glioma, demonstrating improved
anti-tumor response compared to CD alone [24].
Similar to IFN-β, the type II interferon gene, IFN-γ,
is also an immune stimulatory cytokine produced by
NK cells, dendritic cells, and activated T-lymphocytes
[69,170]. IFN-γ inhibits the adhesion of malignant glioma
cells in vitro and diminishes the invasive phenotype of
glioma cells by reducing binding to extracellular matrix
macromolecules [171]. Single-agent activity of IFN-γ
has appeared to be less effective than IFN-β [154] and
Okura et al. Molecular and Cellular Therapies 2014, 2:21 Page 11 of 19
http://www.molcelltherapies.com/content/2/1/21several attempts to focus on the use of combination reg-
imens have been performed. The use of AVs expressing
tumor necrosis factor (TNF)-α or IFN-γ introduced into
tumors enhanced infiltration of CD4 and CD8 positive
T cells in addition to increasing expression of MHC
class I and II on the tumor cells in a mouse glioma
model. Intracranial administration of both vectors led
to a statistically significant increase in survival of tumor
bearing mice [172]. In addition, simultaneous delivery
of IFN-γ inducible protein 10 and TNF-α, both potent
immune-stimulatory cytokines, was attempted in a GBM
mouse model using recombinant parvovirus [173]. The
study demonstrated synergistic activity when using both
vectors and complete regression of tumors generated from
murine glioma cells that had been infected in vitro with
both cytokines before implantation. Although IFN-γ is
thought to have anti-angiogenic properties, cytokine-
mediated immune stimulation was likely responsible for
the therapeutic response [173,174]. IFNs have been the
ideal cytokines to be applied clinically in a variety of
human cancers [154,155]. However, the results of IFN
treatment of most solid tumors have been generally dis-
appointing [175,176]. The unsatisfactory performance
of IFNs in cancer treatments has been in part attributed to
the poor delivery of the protein to the tumor [160,175].
Nevertheless, some reports demonstrated that com-
bination of cytokine gene therapy with conventional
chemotherapy or other types of cytokines show a favor-
able outcome compared to single cytokine gene therapy
[155,169]. In the future, combination gene therapy will
likely become standard protocol for glioma therapy.
Viral-mediated delivery of single interleukins has not
been as extensively investigated in GBM as in other can-
cers, but studies in this direction have definitely shown
therapeutically relevant results [27]. In order to activate
T-cells, a tumor cell must present tumor cell antigen in
the context of MHC class I and simultaneously present
the co-stimulatory antigen. Once the T-cell is activated,
it up-regulates the functional high affinity IL-2 receptor
and secretes IL-2 and −4. The T cell proliferates in re-
sponse to autocrine signals from IL-2 and IL-4 resulting
in an anti-tumor effect [9]. On the other hand, IL-12 is
produced by phagocytes, B cells and DCs following an
encounter with infectious agents. IL-12 acts on T and
NK cells by enhancing the generation and activity of cyto-
toxic lymphocytes and inducing the proliferation and
production of cytokines. IL-12 is the major cytokine re-
sponsible for the differentiation of helper T cells, which
are potent inducers of IFN-γ. IFN-γ, in turn, has a strong
effect on the ability of phagocytes and DCs to produce IL-
12 [177,178]. Consequently, IL-12 has a potent adjuvant
activity in generating anti-cancer effects [177].
In a rat glioma model, recombinant vaccinia virus ex-
pressing the cytokines IL-2 or IL-12 resulted in tumorgrowth inhibition after intratumoral injection [179]. Com-
bination gene therapies of IL-2 and IL-12 proved to be
more effective in increasing the NK, Natural killer T, and
Mac-1+ phagocytic cell populations in blood as well as in-
creased IFN-γ, and TNF-α expression in tumors without
significant toxicity. Non-replicating adenoviral-associated
virus and replicating HSV have also been used to distrib-
ute IL-12 in experimental models of malignant gliomas
[180-182] and the results showed a significant inhibition
of tumor growth and a local immune reaction including
increased IFN-γ expression, microglial activation, and re-
cruitment of T and NK lymphocytes (Figure 3). Colombo
et al. reported using combined delivery of IL-2 with HSV-
TK for 12 patients with recurrent malignant glioma [183].
All patients received a stereotactic or open surgical intratu-
moral injection of retroviral vector-producing cells which
express both the HSV-TK gene and IL-2 gene following by
intravenous GCV. The 12-month progression-free survival
rate and overall survival rates were 14% and 25%, respect-
ively. Although there was a marked increase of circulating
IFN-γ, TNF-α, IL-2, and IL-10, only minor adverse events
were noted [183].
IL-4 is produced by Th2-type T lymphocytes, mast
cells, and basophils [184]. IL-4 increases surface MHC
class II antigen expression in B cells and stimulates the
growth of both helper and cytotoxic T cells, including
tumor infiltrating lymphocytes [185-187]. Therefore, IL-4
is thought to have a potent anti-tumor effect in vivo
against various types of cancer by inducing an immune re-
sponse [188-191]. Okada et al. demonstrated a synergistic
effect using a retrovirally transduced IL-4 plus HSV-TK
gene in a rat intracranial glioma model [192]. This resulted
in a clinical trial using IL-4/HSV-TK gene-modified au-
tologous glioma cells or fibroblasts [193]. Conditionally
replicative oncolytic HSV carrying IL-12 gene therapy will
start in Phase I clinical trial to determine the safety in
patients with recurrent glioma (Table 1).
Tumor suppressor gene therapy
The aim of tumor suppressor gene therapy is to restore
the function of a tumor suppressor gene lost or func-
tionally inactivated in cancer cells (Figure 4). Com-
monly, they regulate diverse cellular activities including
cell-cycle checkpoints, detection and repair of DNA
damage, cell proliferation and apoptosis.
The tumor suppressor gene, P53 is located on chromo-
some 17p and encodes a 393 amino acid protein [194-196].
As the name “Guardian of the Genome” suggests, p53 plays
a critical role in causing cell cycle arrest and apoptosis in
response to a variety of cellular stress such as radiation ex-
posure [197-200]. P53 directly contributes to DNA repair,
and inhibition of angiogenesis [195,199]. The most well-
characterized function of p53 is the inhibition of abnormal
cell growth. Many factors contribute to the control of
Figure 4 Strategy of tumor suppressor gene therapy. Tumor suppressor gene therapy aims to reprogram tumor cells by restoring the
function of a tumor suppressor gene lost or functionally inactivated in cancer cells, subsequently inducing cell cycle arrest or apoptosis.
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crucial in the prevention of tumor development.
Inactivation of p53, which is one of the most com-
monly mutated tumor suppressor genes in glioma, plays
a critical role in glioma progression [113,201]. Alteration
of p53 is seen in approximately 50% of grade II and III
glioma, 25-30% of primary GBM, and 60-70% of second-
ary GBM [202]. Tumor suppressor gene therapy using
p53 in glioma was first tested by delivering this gene
using a replication-deficient AV [27]. The most com-
monly used non-replicating adenoviral vector for p53
gene transfer is the type 5 AV in which the E1 region is
replaced with the cDNA of the p53 gene and is driven
under the control of a CMV promoter (Ad5CMV-p53)
[113,203-209]. Removal of the E1 region makes the virus
replication-defective, reducing the possibility of widespread,
uncontrolled, systemic infection. The CMV promoter is
particularly active in human cells and significantly increases
gene expression [113]. Restoration of the functionally intact
TP53 gene induced robust apoptosis of the infected cells
and inhibited cellular proliferation both in vitro and in vivo
[113,204,207]. There was marked growth inhibition of
implanted gliomas and significant prolongation of sur-
vival in preclinical models [203,208-210]. P53 gene ther-
apy might also suppress angiogenesis of GBM [211].
Several studies have suggested that Ad5CMV-p53 may
be most effective when combined with radiation and
chemotherapy [205,206,212,213]. An additional in vitro
study suggested that combined p53 transfection with
other type of genes such as Fas Ligand, granulocyte–
macrophage colony-stimulating factor and B7-1 enhances
apoptosis and inhibits cell growth [214,215].
Collectively, these preclinical results led to a Phase I
clinical trial of Ad5CMV-p53 gene therapy in recurrent
malignant glioma. Eligible patients underwent stereotactic
injection of the virus pre- and post-resection through an
implanted catheter. Immunohistochemical staining for
p53 protein confirmed exogenous p53 expression withinthe nuclei of glioma cells and induced apoptosis in all
specimens examined. One limitation was revealed when
transduced cells were only found within a short distance
from the injection site. In terms of outcome, the median
progression free survival and overall survival were 13 and
43 weeks, respectively. Of note, one patient was alive more
than three years after treatment without evidence of recur-
rence. The clinical toxicity was minimal without reaching
maximum tolerable dose [216]. Limitations of p53 gene
therapy are considered to be insufficient gene transfer, lack
of bystander effect and tolerance arising from genetic
heterogeneity of glioma [27,217].
Another tumor suppressor gene therapy candidate is
p16INK4A, which causes cell cycle arrest at the G1-S transi-
tion point by stabilizing the hypo-phosphorylated status of
the Rb protein [200,218]. The over-expression of p16 gene
using a recombinant replication-deficient adenovirus
significantly reduced glioma cells invasion as a result of
decreased activity of matrix metalloprotease-2 [218].
The third tumor suppressor gene therapy candidate is
Phosphatase and Tensin Homologue (PTEN) which con-
tains a central catalytic phosphatase core domain that
negatively regulates PI3K by dephosphorylating from
phosphatidylinositol-triphosphate to phosphatidylinositol-
diphosphate [200]. Inactivation of PTEN is seen in 40% to
50% of all gliomas resulting in aberrant activation of PI3K
activity and downstream signaling pathways [219]. Expres-
sion of PTEN in GBM cells caused tumor cell apoptosis
and decrease glioma cell proliferation in vitro [220,221].
Furthermore, adenoviral PTEN expression demonstrated
an anti-angiogenic response in preclinical study [221].
Conclusion
GBM remains one of the most frequent and most clinic-
ally challenging primary brain tumors encountered by
neurosurgeons. Over the past decades, current standard
treatments have evolved to include maximal surgical re-
section followed by adjuvant radiation and chemotherapy.
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with GBM. However, several remarkable advances in the
treatment of GBM have occurred. Surgery augmented
with powerful imaging techniques is aimed at maximal re-
section of tumor tissue without causing new neurological
deficits. Effective reduction of tumor mass can allow the
patients to achieve a better overall survival. Stereotactic
radiosurgery or radiotherapy that attempt to enhance the
effect of other treatment modalities has been developed.
In addition to current standard conventional chemother-
apy for GBM, advancements in our understanding of the
pathogenesis of GBM and the molecular aberrations in
GBM has led to new era of exciting possibilities for the
treatments of GBM.
In the last few decades, a considerable amount of re-
search utilizing gene therapy for glioma has been pub-
lished in in vitro and in animal models. Although most
of these methods have demonstrated success in in vitro
and in pre-clinical studies, a majority of patients in early
clinical studies have ultimately failed to demonstrate sig-
nificant survival for the treatment of GBM. This is partly
because experimental therapies in early clinical study are
usually applied to patients with recurrent or advanced
GBM disease, who have often been treated with multiple
treatment regimes, including radiation or chemotherapy
(TMZ) or both. These patient tumors are likely already
beyond a curable level and a modest response can be ex-
pected even with a well established therapy at the time
of the trial and this likely contributes to the low success
rate observed in clinical trials. For proper evaluation of
efficacy, patients with earlier stages of GBM need to be
enrolled in clinical studies.
A number of specific difficulties are associated with gene
therapy for GBM including: limited transduction efficiency
of the viral vectors; lack of a delivery system that bypasses
the BBB; inability to distinguish tumor cells from normal
cells; and the selective expression of a transgene in aTable 2 Comparison of gene therapy strategies for GBM
Suicide gene therapy Oncolytic gene therapy Cytokine






● Bystander effect ● Selective toxicity ● Combin
types of g




▲ Transduced cells may become
resistant to the prodrug




▲ Low efficiency for distribution ▲ Cerebral inflammation
and edema
▲ CNS to
▲ Low delivery to target cells ▲ Poor d
tumor
▲ Limited prolonged efficacy
●, Advantages; ▲, Disadvantages.therapeutically controlled manner (Table 2). The histo-
logical heterogeneity of the cell population within the
tumor is considered to be another major impediment. The
restricted intratumoral distribution of the viral vector still
remains an issue for obtaining optimal clinical efficacy due
to the infiltrative nature of GBM. Greater vector stability,
as well as prolonged therapeutic transgene expression,
might result in more efficacious treatment of GBM.
Therefore, in order to improve gene therapy efficiency,
new vectors should overcome the limited infiltration
and transgene expression that occurs after administra-
tion. In addition to viral vectors, stem cells have been
successfully used to deliver therapeutic gene products
to primary and secondary invasive brain tumors. They-
have demonstrated their usefulness in combined gene
therapy such as suicide gene therapy and cytokine gene
therapy. Another important property is the stem cell’s
ability to migrate toward infiltrative GBM tumors even
when administered peripherally. Stem cells may become
an important vector option in gene therapy for GBM.
Gene therapy alone will not likely provide a cure of
GBM, at least not in the near future. Since GBM is a het-
erogeneous tumor, therapeutic blocking of one or two
pathways may simply result in the activation of alternative
pathways leading to continuous tumor progression. There-
fore, simply replacing a single lost gene (i.e. tumor sup-
pressor gene) never brings about success in treatment of
GBM. However, gene therapy was able to demonstrate
significant anti-cancer effects in other types of cancers
including melanoma, hepatocellular carcinoma, and squa-
mous cell carcinoma in head and neck, suggesting that
gene therapy still has a great potential for inclusion in
GBM treatment protocols. Furthermore, multiple options
are now available, including more complex systems involv-
ing combination of suicide genes or oncolytic virotherapy
with immunological or tumor suppressor genes, selectively
replicating viruses, and non-viral vectors. It is likely thatmediated gene therapy Tumor suppressor gene therapy
gmentation of the
esponse inside the brain
● Anti-angiogenesis effect
ation therapy with other
ene therapy available
● Synergistic therapeutic efficiency of
conventional or other of gene therapy
tumor vascularization and
f antigen presenting cells
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ment modalities, such as advanced radiation therapy and
molecular targeted therapy, would demonstrate greater
efficacy over the treatment with viral agents alone. For
instance, brain radiotherapy can disrupt the BBB facili-
tating enhanced viral delivery. Patient safety does not
appear to be a significant concern in the clinical gene
therapy studies in patients with GBM. Although an ideal
vector has yet to be developed, future treatment of
GBM will likely incorporate multimodal therapy to
study synergistic relationships between improved gene
therapy and current radiation and chemotherapeutic
regimens. A significant obstacle to the development of
multidrug combination clinical trial protocols includes
legal entanglements that preclude a drug from one com-
pany from being combined with a second. The design of
combination protocols including gene therapies may ul-
timately alleviate some of these legal obstructions. As the
field of gene therapy moves forward, the use of gene ther-
apy in the treatment of GBM will become an increasingly
promising area of research to support the therapeutic regi-
mens of surgery, radiation, and chemotherapy.
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